Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABPNASDAQ:IOBTNASDAQ:PYXSNASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.25-6.5%$0.55$0.23▼$13.00$12.75M-0.0790,518 shs180,522 shsIOBTIO Biotech$0.89+0.2%$0.96$0.66▼$1.79$58.63M0.08272,926 shs70,192 shsPYXSPyxis Oncology$0.93+2.1%$1.11$0.83▼$5.39$57.52M1.17724,381 shs354,745 shsUNCYUnicycive Therapeutics$0.60+0.7%$0.57$0.20▼$1.29$71.58M2.151.44 million shs212,822 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-6.46%-5.38%-50.39%-81.78%+24,599,900.00%IOBTIO Biotech+0.24%+1.37%-1.11%+10.01%-42.21%PYXSPyxis Oncology+2.07%-5.23%-19.49%-36.47%-80.09%UNCYUnicycive Therapeutics+0.74%+16.80%+2.93%-2.61%-46.84%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AIOBTIO Biotech2.8955 of 5 stars3.73.00.00.03.20.81.3PYXSPyxis Oncology1.3645 of 5 stars3.40.00.00.03.00.00.6UNCYUnicycive Therapeutics2.8334 of 5 stars3.73.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,526.02% UpsideIOBTIO Biotech 3.33Buy$9.33948.69% UpsidePYXSPyxis Oncology 2.83Moderate Buy$9.20885.12% UpsideUNCYUnicycive Therapeutics 3.33Buy$5.25777.93% UpsideCurrent Analyst Ratings BreakdownLatest ABP, UNCY, IOBT, and PYXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/1/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/1/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.503/19/2025PYXSPyxis OncologyRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/12/2025IOBTIO BiotechPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/5/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.002/24/2025ABPAbproMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.001/29/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 4/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$122K104.48N/AN/AN/A∞IOBTIO BiotechN/AN/AN/AN/A$2.02 per shareN/APYXSPyxis Oncology$16.15M3.56N/AN/A$2.81 per share0.33UNCYUnicycive Therapeutics$680K105.27N/AN/A($0.11) per share-5.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbproN/AN/A0.00∞N/AN/AN/AN/AN/AIOBTIO Biotech-$86.08M-$1.37N/AN/AN/AN/A-86.56%-75.24%5/13/2025 (Estimated)PYXSPyxis Oncology-$73.79M-$1.30N/AN/AN/AN/A-36.22%-28.76%5/13/2025 (Estimated)UNCYUnicycive Therapeutics-$30.54M-$1.07N/AN/AN/AN/AN/A-29.88%5/12/2025 (Estimated)Latest ABP, UNCY, IOBT, and PYXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IOBTIO Biotech-$0.45N/AN/AN/AN/AN/A5/13/2025Q1 2025PYXSPyxis Oncology-$0.29N/AN/AN/AN/AN/A5/12/2025N/AUNCYUnicycive Therapeutics-$0.14N/AN/AN/AN/AN/A3/27/2025Q4 2024UNCYUnicycive Therapeutics-$0.13-$0.26-$0.13-$0.26N/AN/A3/18/2025Q4 2024PYXSPyxis Oncology-$0.33-$0.32+$0.01-$0.60N/A$16.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/AN/AN/AIOBTIO BiotechN/A5.375.37PYXSPyxis OncologyN/A7.337.33UNCYUnicycive TherapeuticsN/A3.613.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%IOBTIO Biotech54.76%PYXSPyxis Oncology39.09%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipABPAbpro19.80%IOBTIO Biotech2.30%PYXSPyxis Oncology9.80%UNCYUnicycive Therapeutics24.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1551.82 million4.57 millionN/AIOBTIO Biotech3065.88 million64.37 millionNot OptionablePYXSPyxis Oncology6061.59 million53.64 millionOptionableUNCYUnicycive Therapeutics9119.71 million78.78 millionNot OptionableABP, UNCY, IOBT, and PYXS HeadlinesRecent News About These CompaniesUnicycive Therapeutics' (UNCY) Buy Rating Reiterated at HC WainwrightApril 14 at 1:45 AM | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Unicycive Therapeutics (NASDAQ:UNCY)April 13, 2025 | marketbeat.comUnicycive presents new patient-level data from Phase 2 study of OLCApril 12, 2025 | markets.businessinsider.comResearch Analysts Offer Predictions for UNCY FY2025 EarningsApril 6, 2025 | marketbeat.comHC Wainwright Analysts Reduce Earnings Estimates for UNCYApril 6, 2025 | marketbeat.comBrookline Capital Management Estimates UNCY Q1 EarningsApril 5, 2025 | marketbeat.comUnicycive Therapeutics price target raised to $7.50 from $4 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comNoble Financial Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)April 2, 2025 | markets.businessinsider.comHC Wainwright Increases Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $7.50April 2, 2025 | marketbeat.comUnicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPSApril 1, 2025 | marketbeat.comUnicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comUnicycive Therapeutics reports FY24 EPS (56c), consensus (51c)April 1, 2025 | markets.businessinsider.comUnicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | globenewswire.comUnicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on ThursdayMarch 20, 2025 | marketbeat.comUnicycive to present patient reported outcomes data from UNI-OLC-201 studyMarch 13, 2025 | markets.businessinsider.comUnicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of HyperphosphatemiaMarch 13, 2025 | globenewswire.comUnicycive Therapeutics’ OLC shows synergy with tenapanor in published studyFebruary 21, 2025 | markets.businessinsider.comUnicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360February 20, 2025 | globenewswire.comBuy Rating for Unicycive Therapeutics Driven by Promising OLC Treatment and Reduced Pill BurdenJanuary 29, 2025 | markets.businessinsider.comUnicycive highlights challenges in phosphate managementJanuary 28, 2025 | msn.comUnicycive announces publication of patient perspectives on phosphate managementJanuary 28, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABP, UNCY, IOBT, and PYXS Company DescriptionsAbpro NASDAQ:ABP$0.25 -0.02 (-6.46%) As of 04/16/2025 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.IO Biotech NASDAQ:IOBT$0.89 +0.00 (+0.24%) As of 04/16/2025 03:58 PM EasternIO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Pyxis Oncology NASDAQ:PYXS$0.93 +0.02 (+2.07%) Closing price 04/16/2025 04:00 PM EasternExtended Trading$0.94 +0.01 (+1.19%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Unicycive Therapeutics NASDAQ:UNCY$0.60 +0.00 (+0.74%) As of 04/16/2025 04:00 PM EasternUnicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Eyes Breakout With Earnings on Deck Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited Viking Therapeutics Stock Pops But Struggles to Hold Gains Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Lemonade: Leveraging AI to Underwrite a Path to Profitability 2 Penny Stocks With $10 Potential Congress! Who Traded What During the Tariff-Induced Meltdown Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
